Page 11 - கலைக்கழகம் ஆஃப் மருத்துவ அறிவியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

 E-Mail Interim data from a phase 3 trial of a COVID-19 vaccine developed in China (CoronaVac) suggests that two doses offer 83.5% protection against symptomatic COVID-19. The preliminary findings, published in The Lancet and presented at this year s European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), indicate that CoronaVac induces a robust antibody response. No severe adverse events or deaths were reported among the more than 10,000 trial participants in Turkey, with most adverse events mild and occurring within 7 days of an injection. However, more research is needed to confirm vaccine efficacy in the long term, in a more diverse group of participants, and against emerging variants of concern.

Murat akovaAcademy of medical sciencesResearch hospitalMarmara universityKocaeli universityHacettepe university medical schoolKaradeniz technical universitySinovac life sciencesDicle university yedikule chest diseasesDege universityEuropean congressAkdeniz universityGaziantep universityUniversity of oxford astrazenecaTurkish health institutes associationAnkara university